The epidemiological and clinical importance of bone metastases has long been recognised. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40 0n metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on the patient's quality of life. This volume presents a broad approach to recent progress in all fields related to bone metastases, ranging from epidemiology to the physiopathology of bone metastases and therapeutics. It attempts to provide a better understanding of recent advances and, more importantly, should give clinicians all the information needed to help them in the clinical and therapeutic management of patients with bone metastases.